Clinical report: Proof of concept for Allay’s implantable analgesic, with Singapore tech
Plus: Intra-Cellular’s Caplyta scores a win in major depressive disorder; and readouts for Marinus, Ultragenyx weigh on shares
Allay has achieved clinical proof of concept for an implant that promises durable, opioid-free pain relief following surgery. The milestone not only sets up the company for a pivotal Phase IIb study, but also helps build confidence in the increasingly popular strategy of translating Singaporean science through international collaboration.
The bioresorbable polymer technology that forms the basis of Allay Therapeutics Inc.’s pipeline was developed by scientists in Singapore, where the biotech ecosystem remains young, but the quality of the academic research has piqued the interest of international investors. The dominant model for translating Singapore’s innovation is one of external collaboration: typically pairing R&D in Singapore with U.S. management and a multiregional investor syndicate. Allay fits this mold, with its CEO and clinical development team located in the U.S...